US Job Growth Defies Gloom as Bitcoin Slips Below $76k; Trump’s Triumphal Arch Blocked by DC Judge

US Labor Market Resilience Rattles Crypto and Gold

The United States Bureau of Labor Statistics (BLS) released its October employment report on Friday, revealing a surprisingly resilient economy that added 165,000 jobs. This figure comfortably exceeded economist expectations, despite the dual pressures of persistent inflation and geopolitical instability in the Middle East. The unemployment rate ticked down slightly to 4.1%, painting a picture of a "low-hire, low-fire" environment where, although growth isn't explosive, the floor is holding firm. This strength has immediate implications for monetary policy, as traders now price in a higher probability of an interest rate hike in December to prevent the economy from overheating.

The market reaction was swift and decisive. Bitcoin (BTC), which had been flirting with record highs, dropped below the $76,000 mark to trade around $75,328 as investors digested the "hot" jobs data. Higher employment often signals that the Federal Reserve will keep borrowing costs elevated for longer, which traditionally dampens the appeal of non-yielding assets like cryptocurrencies and gold. In the Tehran market, this global shift mirrored a local cooling; the price of 18k gold per gram fell from 26,086,153 to 25,786,047 Toman, a decline of 1.2%, reflecting both global technical selling and a slight easing of local speculative pressure.

Coordinated Bomb Threats Disrupt European Skies

European aviation was thrown into chaos on Friday following what Irish government officials have described as a "likely coordinated campaign of disruption." A series of bomb threats targeted multiple flights across the continent, including a Tarom flight from Prague to Bucharest. The aircraft was forced to issue a 7700 emergency squawk code before landing safely, where the threat was eventually deemed a hoax. However, the scale and timing of these threats—distributed across various media organizations and airlines—suggest a deliberate attempt to test security responses and incite panic in the European "grey zone."

Security analysts are viewing these incidents not as isolated pranks, but as a form of hybrid warfare designed to strain infrastructure and psychological resilience. While no group has claimed responsibility, the sophistication of the communication suggests a level of organization beyond typical lone-wolf actors. For travelers and markets, this adds a layer of geopolitical risk premium to European transport and insurance sectors. The Irish government’s vocal response underscores a growing concern among EU members that such disruptions are becoming a tool for state or state-sponsored actors to exert pressure without engaging in direct kinetic conflict.

Legal Blow to Trump’s Triumphal Arch and Moderna’s Pivot

In Washington D.C., Federal Judge Tanya Chutkan has issued a 14-day temporary restraining order, halting all construction work on Donald Trump’s proposed "triumphal arch." The monument, intended to be a centerpiece of the president's vision for a redesigned capital, had recently received planning commission approval but faced immediate legal challenges regarding its environmental impact and historical preservation compliance. Judge Chutkan, who has presided over several high-profile cases involving the president, noted that the stay is necessary to allow for a more thorough judicial review of the project’s legality. This pause represents a significant symbolic and logistical setback for one of the administration's most personal infrastructure goals.

On the corporate front, Moderna has provided a rare bright spot for the biotech sector by raising its 2026 revenue outlook. The company now expects revenue growth of up to 25%, driven by its expansion into oncology. While its COVID-19 vaccine revenue continues to normalize, all eyes are now on its experimental cancer vaccines, which are entering critical trial phases. This pivot highlights a broader trend in the pharmaceutical industry: the transition from pandemic-era emergency response to long-term, high-margin specialized medicine. Investors are cautiously optimistic, though the path to regulatory approval for mRNA-based cancer treatments remains fraught with clinical hurdles.